Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Diagnos Inc. (OTC: DGNOF).

Full DD Report for DGNOF

You must become a subscriber to view this report.


Recent News from (OTC: DGNOF)

DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease
BROSSARD, Quebec, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence ( AI ), announces today an agr...
Source: GlobeNewswire
Date: September, 05 2018 09:00
DIAGNOS announces private placement of common stocks and stock warrants
DIAGNOS Inc. ( OTCQB:DGNOF ) announces a private placement of up to 1.33M units issued at $0.075 per Unit for gross proceeds of up to $0.1M. More news on: Diagnos Inc., Read more ...
Source: SeekingAlpha
Date: August, 24 2018 13:09
DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants
BROSSARD, Quebec, Aug. 24, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (&#x...
Source: GlobeNewswire
Date: August, 24 2018 12:24
DIAGNOS Provides Update on Business Operations
BROSSARD, Quebec, July 31, 2018 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, “the Corporation” or “We”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence ( AI ), annou...
Source: GlobeNewswire
Date: July, 31 2018 09:00
DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama
BROSSARD, Quebec, July 10, 2018 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence ( AI ), announces today the inst...
Source: GlobeNewswire
Date: July, 10 2018 09:00
DIAGNOS Closes Second and Final Tranche of Private Placement
BROSSARD, Quebec, July 05, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FL AI RE platform based on Artificial Intelligenc...
Source: GlobeNewswire
Date: July, 05 2018 14:08
DIAGNOS Broadens its Collaboration with the Government of Mexico
BROSSARD, Quebec, July 04, 2018 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence ( AI) , announces today an expansion o...
Source: GlobeNewswire
Date: July, 04 2018 09:52
DIAGNOS Provides Financing Updates
BROSSARD, Quebec, June 29, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FL AI RE platform based on Artificial Intelligenc...
Source: GlobeNewswire
Date: June, 29 2018 14:00
DIAGNOS Hires Investor Relation Firm Momentum Public Relations and Provides Financing Update
BROSSARD, Quebec, June 14, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FL AI RE platform based on Ar...
Source: GlobeNewswire
Date: June, 14 2018 14:52
DIAGNOS Announces the Availability of its New CARA High Blood Pressure Risk Assessment Based on its FLAIRE Artificial Intelligence Platform
BROSSARD, Quebec, June 12, 2018 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FL AI RE platform based on Artificial Intelligence...
Source: GlobeNewswire
Date: June, 12 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A0.024N/AN/A0
2018-12-06N/A0.024N/AN/A0
2018-12-050.02530.0240.02530.024196,000
2018-12-040.02530.0240.02530.024196,000
2018-12-030.0290.0290.0290.02950,000

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0446,000196,00023.4694Cover
2018-11-154,0004,000100.0000Short
2018-11-0950,00050,000100.0000Short
2018-11-072,00039,0005.1282Cover
2018-10-302,8203,00094.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DGNOF.


About Diagnos Inc. (OTC: DGNOF)

Logo for Diagnos Inc. (OTC: DGNOF)

Founded in , DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence AI tool CARA Computer Assisted Retina Analysis . CARA is a tele ophthalmology platform that integrates with existing equipment hardware and software and processes at the point of care POC . CARA s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and in Mexico.

 

Contact Information

 

 

Current Management

  • Andre Larente / President
    • Mr. Larente has been active in the information technology sector for more than years. He has previously held leading management positions with companies such as Siemens, Syscan International, Newbridge Networks, Legent Corporation, Cognos, Tandem Computers and Honeywell Information Systems. His extensive business contacts and experience in the information technology sector, have enabled him to position DIAGNOS for rapid growth.
  • MarcAndre Massue / CFO
    • Mr. Massue joined the team in May . He has more than years of financial and human resources management experience, acquired mainly with technology companies. Mr. Massue s main responsibilities include the preparation of the annual and quarterly reports, the preparation of investment tax credits claims and the development and monitoring of internal management policies. Mr. Massue received a Bachelor in Business Administration BBA from HEC Montreal, and a Diploma in Economics from the Universite de Montreal. Mr. Massue is a member of the Quebec Order of Chartered Accountants.
  • Guillermo Moreno Robles / VP, Sales
    • Mr. Moreno Robles joins DIAGNOS Inc., as DirectorBusiness Development, with the aim of supporting strategic deployment of corporation s overseas business portfolio. Holding a Master in Economics UIBE China , a Master in ECommerce Tec de Monterrey Mexico and BBA/Licence Commerce et Affaires Internationales Universite Lumiere Lyon France , Mr. Moreno Robles competences and nineyears of proven experience in the world of business by representing Mexico s government in ChinaAsia Pacific region, providing economic consulting to investors, coaching business promotion in the international arena, now takes part of DIAGNOS shared values and global leadership in the IT private sector.
  • Dr. Hadi Chakor / CMO
    • Dr. Hadi Chakor MD, MSc, PhD successfully completed his medical school diploma with a specialization in ophthalmology. He then further completed his master s degree in biomedical engineering in the field of visual electrophysiology evaluation of the functional aspect of the retina at the University of Montreal , followed by a Doctorate PhD in biomedical sciences that specifically focused on the prevention of coronary heart disease through the early presence of retinal microvascular abnormalities for a population at risk in collaboration with the Montreal Heart Institute and the University of McGill s department of ophthalmology . His research was funded by the FRSQ and the FICM heart disease foundation. It should also be noted that he is the recipient of the JeanLouis L vesque Award, FICM . His expertise of over years as a clinical researcher and consultant for various governmental bodies and universities has led to my occupation of several research and development positions including being a researching consultant for the National Health and Social Services Excellence Institute INESS . He is the author and coauthor of national, international and institutional presentations and publications in the field of ophthalmology and I have participated in the publication of several governmental reports on the prevention and optimization of health care in Canada.
  • Cindy Mercier / Contact Person
  • Georges Herbert / Chairman
    • Mr. Hebert brings a wealth of experience in governance of public and private companies. He was a director at the Laurentian Bank, where he served for twenty years as a member of the Audit committee. He was also a director of Vitran Corp for seven years, where he served as a member of the Audit committee and chairman of the Compensation committee. He is currently president of ProsysTec Inc. and a director of Cubeler Inc., a private Fintech company.
  • Tristram Coffin / Director
    • Mr. Coffin, a Montreal businessman entrepreneur, was admitted to the Order of Opticians in . His team spirit and dynamism allowed him to become one of Quebec s most prominent purveyor of quality eyewear and eye care services. He is also a director of Metanor Resources and has actively helped the company become a gold producer.
  • Andre Larente /
  • JeanYves Therien / Director
    • Mr. Th rien holds a Bachelor degree in Administration specialized in finances from l UQAM. He has worked for years as financial advisor for multiple brokerage Companies. JeanYves was Vice President of the Diabetes Association of Laval/Laurentide from January April and also President of the corporate finance campaign from January January . The city of Laval, Quebec is the third largest city in the province of Quebec. His team spirit, entrepreneurship, perseverance and dynamism allow Nippon Dragon to establish a niche in the industry and to exploit markets never developed before.

Current Share Structure

  • Market Cap: $10,379,760 - 03/15/2018
  • Issue and Outstanding: 172,421,265 - 12/31/2017

 



Daily Technical Chart for (OTC: DGNOF)

Daily Technical Chart for (OTC: DGNOF)


Stay tuned for daily updates and more on (OTC: DGNOF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DGNOF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DGNOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DGNOF and does not buy, sell, or trade any shares of DGNOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/